Docetaxel
Key facts
| Invented name |
Taxotere
|
| Active substance |
docetaxel
|
| Therapeutic area |
Oncology
|
| Decision number |
P/22/2008
|
| PIP number |
Docetaxel
|
| Pharmaceutical form(s) |
Concentrate and solvent for solution for infusion
|
| Condition(s) / indication(s) |
Nasopharyngeal carcinoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Aventis Pharma SA
E-mail: sylvie.gabriel@sanofi-aventis.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|